GUTS (Fractyl Health) Pre-Tax Income : $-62.90 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Fractyl Health Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Fractyl Health's pretax income for the three months ended in Sep. 2024 was $-23.17 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-62.90 Mil. Fractyl Health's pretax margin was -165,521.43%.

During the past 5 years, Fractyl Health's highest Pretax Margin was -64242.50%. The lowest was -64849.49%. And the median was -64242.50%.

Fractyl Health Pre-Tax Income Historical Data

The historical data trend for Fractyl Health's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fractyl Health Pre-Tax Income Chart

Fractyl Health Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-30.59

-30.48

-38.74

-46.45

-77.09

Fractyl Health Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial												-15.75	-19.18	-3.32	-17.23	-23.17

Competitive Comparison of Fractyl Health's Pre-Tax Income

For the Biotechnology subindustry, Fractyl Health's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fractyl Health's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fractyl Health's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Fractyl Health's Pre-Tax Income falls into.

Fractyl Health Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Fractyl Health's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-50.836	+	-27.515	+	0	+	1.26	+	0
	=	-77.09

Fractyl Health's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-23.794	+	-0.326	+	0	+	0.947	+	3.5527136788005E-15
	=	-23.17

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.90 Mil.

Fractyl Health (NAS:GUTS) Pre-Tax Income Explanation

Fractyl Health's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-23.173	/	0.014
	=	-165,521.43%

During the past 5 years, Fractyl Health's highest Pretax Margin was -64242.50%. The lowest was -64849.49%. And the median was -64242.50%.

Fractyl Health Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Fractyl Health's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Fractyl Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fractyl Health Inc (NAS:GUTS) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Van de Graaff Drive, Suite 200, Burlington, MA, USA, 01803

Website

https://www.fractyl.com

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.